US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INVESCO BIOTECHNOLOGY & GENOME ETF

92.91

-0.1200-0.13%

Post-market: 92.910.00000.00%19:30 EDT

Volume:11.40K

Turnover:1.06M

Market Cap:403.23M

PE:51.81

High:93.97

Open:93.28

Low:92.77

Close:93.03

52wk High:98.82

52wk Low:67.69

Shares:4.34M

Float Shares:4.34M

Volume Ratio:1.07

T/O Rate:0.26%

Dividend:1.54

Dividend Rate:1.66%

EPS(TTM):1.79

EPS(LYR):18.65

ROE:24.76%

ROA:0.08%

PB:1.63

PE(LYR):4.98

Loading ...

Overview Company News Filings

Sino Biopharmaceutical Stock Slides 1.2% in Hong Kong, Underperforms Competitors

Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs

Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares

A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts

Royalty Pharma Announces Update on Novartis’ Phase 3 Topline Results for Pelacarsen

THOMSON REUTERS

Royalty Pharma - Expects to Recoup Investment and Earn Modest Return Despite Pelacarsen Failure

THOMSON REUTERS

Amgen EVP, CFO Thomas J.W. Dittrich Files Initial Beneficial Ownership Statement

Amgen is Maintained at Equal-Weight by Wells Fargo

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Alnylam's Zilebesiran Sees Commercial Opportunity From Baxfendy Launch, Oppenheimer Says

MT Newswires Live

Correction: Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi

MT Newswires Live

Stoke Therapeutics, Biogen present long-term data on Zorevunersen

Stoke Therapeutics, Biogen Report 4-Year Open-Label Data for Dravet Drug Zorevunersen Showing Durable Seizure Reduction

Stoke Therapeutics and Biogen Present Long-Term Clinical Data That Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)

THOMSON REUTERS

Vortex Energy to Launch Ground Gravity Survey at Robinsons River Salt Project

Political and General News Events from September 3

Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi

Sino Biopharmaceutical Stock Rises 6.3% in Hong Kong, Outperforms Competitors

Biogen : Piper Sandler Raises Target Price to $245 from $225

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/PBE/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PBE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","market":"US","secType":"STK","nameCN":"INVESCO BIOTECHNOLOGY & GENOME ETF","latestPrice":92.91,"timestamp":1789156800000,"preClose":93.03,"halted":0,"volume":11398,"hourTrading":{"tag":"盘后","latestPrice":92.91,"preClose":92.91,"latestTime":"19:30 EDT","volume":228,"amount":21182.6408,"timestamp":1789169404932,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0012899064817801199,"floatShares":4340000,"shares":4340000,"eps":1.793292,"marketStatus":"Market Closed","change":-0.12,"latestTime":"09-11 16:00:00 EDT","open":93.28,"high":93.97,"low":92.77,"amount":1062234.170828,"amplitude":0.012899,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":1.793292,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":93.03,"sharesOutstanding":3180000,"nav":93.09028,"aum":405873620.8,"dividendRate":0.016621,"bidAskSpread":0.002101,"postHourTrading":{"tag":"盘后","latestPrice":92.91,"preClose":92.91,"latestTime":"19:30 EDT","volume":228,"amount":21182.6408,"timestamp":1789169404932,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0673683676295047,"impliedVol":0.0627,"impliedVolPercentile":0.008},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","floatShares":4340000,"roa":"0.08%","roe":"24.76%","lyrEps":18.654418,"volumeRatio":1.0673683676295047,"shares":4340000,"dividePrice":1.5443,"high":93.97,"amplitude":0.012899,"preClose":93.03,"low":92.77,"week52Low":67.69,"pbRate":"1.63","psRate":"234.89","week52High":98.82,"institutionHeld":0.2552,"latestPrice":92.91,"eps":1.793292,"divideRate":0.016621,"volume":11398,"delay":0,"ttmEps":1.793292,"open":93.28,"prevYearClose":82.15,"prevWeekClose":97.6367,"prevMonthClose":96.68,"prevQuarterClose":89.6486,"fiveDayClose":98.7191,"twentyDayClose":94.2238,"sixtyDayClose":84.12},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBE\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"PBE","amount":0.81061,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"PBE","amount":0.08244,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"PBE","amount":0.41972,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"PBE","amount":0.23409,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PBE","amount":0.13047,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBE\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-30","value":0.02834,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.1208,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-31","value":0.05552,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-30","value":0.21532,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00207,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBE\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665739003","title":"Sino Biopharmaceutical Stock Slides 1.2% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2665739003","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665739003?lang=en_us&edition=fundamental","pubTime":"2026-09-07 16:32","pubTimestamp":1788769920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. shed 1.2% to 5.47 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 25413.12.This was the stock's second consecutive day of losses.Sino Biopharmaceutical Ltd. closed 40% below its 52-week high of HK$9.12, which the company reached Sept. 10.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. fell 0.1% and Amgen Inc. remained unchanged.Trading volume totaled 42.8 million shares, compared to the 50-day average of 101.5 million shares.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","IBB","PJP","BK1191","BK4599","LU0868494617.USD","LU2089984988.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4566","BK4588","BK1521","IE00BZ08YT58.USD","LU0889565916.HKD","LU2112291526.USD","LU0320765992.SGD","BK4581","IE00BJT1NW94.SGD","LU0122379950.USD","BK4585","LU1061106388.HKD","LU2242652126.USD","LU1023059063.AUD","BK1589","IBBQ","BK4139","IE00B2B36J28.USD","LU1983299246.USD","01177","BIB","LU0289739699.SGD","BK1515","SG9999001440.SGD","AMGN","BK4534","LU1057294990.SGD","LU1571399168.USD","TBXU","BK4533","IE0009355771.USD","LU2468319806.SGD","IE0002141913.USD","LU0058720904.USD","LU0109394709.USD","PBE","IE00BJJMRZ35.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BBH","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665390614","title":"Novartis Cholesterol Setback Tests Hopes for Emerging Heart Disease Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665390614","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665390614?lang=en_us&edition=fundamental","pubTime":"2026-09-07 16:11","pubTimestamp":1788768672,"startTime":"0","endTime":"0","summary":"UPDATE 2-Novartis cholesterol setback tests hopes for emerging heart disease drugsLONDON, Sept 7 (Reuters)-Shares of NovartisNOVN.Sfell more than 3% on Monday after its cholesterol drug failed in a cl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nL1N44Z05O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELIL","LU2089284900.SGD","MEDI","MHIP","BBH","IYH","PJP","BIB","LU1571399168.USD","LLY","VHT","JDOC","TRUH","FHLC","IE00BJJMRY28.SGD","LLYX","SGXZ99366536.SGD","WDNA","IBB","LU1691799644.USD","RXL","PBE","SLN","XLV","LU2361044865.SGD","OZEM","PPH","ELIS","LU1267930730.SGD","MEDX","LU0823434583.USD","LU0097036916.USD","FTXH","IXJ","NAMS","LLYZ","AMGN","LU2750360641.GBP","AGNG","GDOC","IBBQ","TBXU","CANC","TMED","HRTS","THNR","LLII","ILDR","IHE","CURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104786890","title":"Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1104786890","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104786890?lang=en_us&edition=fundamental","pubTime":"2026-09-07 15:22","pubTimestamp":1788765738,"startTime":"0","endTime":"0","summary":"Swiss pharma giant Novartis AG (NVS.US) has suffered another clinical trial setback, marking the second high-profile candidate to fail in late-stage studies within a single week. The latest casualty...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","IE0002141913.USD","LU0320765992.SGD","LU0889565916.HKD","TBXU","LU1061106388.HKD","PBE","IE00B4R5TH58.HKD","BK4007","LU0208291251.USD","IBB","IE00B2B36J28.USD","LU1023059063.AUD","AMGN","LU2242646821.SGD","MEDX","SG9999001440.SGD","LU0211331839.USD","BK4581","LU0058720904.USD","NVS","PJP","LU1057294990.SGD","LU1571399168.USD","BK4585","BK4566","LU2089984988.USD","BK4534","PPH","LU2242652126.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4139","IE00BJJMRZ35.SGD","BK4599","BK4532","LU0320765489.SGD","LU0868494617.USD","LU0122379950.USD","LU1983299246.USD","LU2112291526.USD","BBH","BK4533","BK4578","IE0009355771.USD","BK4588","BIB","IBBQ","LU0289739699.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365115","title":"A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365115","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665365115?lang=en_us&edition=fundamental","pubTime":"2026-09-06 02:01","pubTimestamp":1788631260,"startTime":"0","endTime":"0","summary":"In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.Novartis saw U.S.-listed shares soar","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IYF","LU0211331839.USD","PPH","LU1074936037.SGD","LU2242652126.USD","LU2456880835.USD","BK4504","LU2462157665.USD","MEDX","LU0868494617.USD","LU1244550221.USD","LU0980610538.SGD","BK4559","LU0070302665.USD","LU2360032135.SGD","FTXO","LU2112291526.USD","LU2236285917.USD","PJP","LU0128525689.USD","BK4599","LU1061106388.HKD","TFNS","BBH","TBXU","SG9999001440.SGD","LU0320765489.SGD","LU0106831901.USD","BK4581","LU2242646821.SGD","LU0052756011.USD","LU1162221912.USD","LU0130102774.USD","LU1983299246.USD","NVS","IBB","LU0314106906.USD","BK4139","IBBQ","BK4533","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2125154935.USD","LU1057294990.SGD","IE00BSNM7G36.USD","BK4007","BK4566","PBE","BIB","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665682593","title":"Aclaris, EyePoint, Vertex, GitLab, NioCorp Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2665682593","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665682593?lang=en_us&edition=fundamental","pubTime":"2026-09-05 17:01","pubTimestamp":1788598891,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($ACRS) ), ( ($EYPT) ), ( ($VRTX) ), ( ($GTLB) ) and ( ($NB) ). Here is a breakdown of their recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/aclaris-eyepoint-vertex-gitlab-niocorp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/aclaris-eyepoint-vertex-gitlab-niocorp-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2456880835.USD","LU0757428866.USD","BIB","LU1035775433.USD","LU0234570918.USD","IE0009355771.USD","BK4533","VERX","EYPT","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU2417539215.USD","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","IE00B19Z9Z06.USD","LU1093756168.USD","VRTX","LU2089984988.USD","LU2236285917.USD","BK4607","TBXU","IE00B2B36J28.USD","LU1559883803.SGD","IE00B4R5TH58.HKD","LU2468319806.SGD","PBE","LU2462157665.USD","IE00BZ9MQY76.HKD","IDNA","LU1674673428.USD","SG9999013999.USD","BK4613","IBBQ","LU0289739699.SGD","GNMX","GTLB","LU2362541513.USD","IE00B19Z9P08.USD","BK4097","LU0417517546.SGD","LU1778281490.HKD","SG9999001176.SGD","LU2324357040.USD","IE0002270589.USD","LU0079474960.USD","IBB","IE00B894F039.SGD","IE0002141913.USD","LU1093756325.SGD","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665935260","title":"Royalty Pharma Announces Update on Novartis’ Phase 3 Topline Results for Pelacarsen","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935260","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665935260?lang=en_us&edition=fundamental","pubTime":"2026-09-05 07:05","pubTimestamp":1788563100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA8S5T7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RPRX","PBE","IHE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352983","title":"Royalty Pharma - Expects to Recoup Investment and Earn Modest Return Despite Pelacarsen Failure","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352983","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665352983?lang=en_us&edition=fundamental","pubTime":"2026-09-05 07:05","pubTimestamp":1788563100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA8S5T7L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IHE","RPRX","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665352504","title":"Amgen EVP, CFO Thomas J.W. Dittrich Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2665352504","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665352504?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:53","pubTimestamp":1788562416,"startTime":"0","endTime":"0","summary":"Amgen EVP, CFO Thomas J.W. Dittrich files initial beneficial ownership statementAmgen EVP and CFO Thomas J.W. Dittrich reported 16,860 common shares in an initial SEC Form 3 filing.Disclaimer:This new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL6SPhM6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU2112291526.USD","LU0289739699.SGD","LU2089984988.USD","PBE","PJP","AMGN","BK4534","LU1061106388.HKD","BK4599","BIB","BK4533","LU0109394709.USD","LU0320765992.SGD","LU1057294990.SGD","LU1571399168.USD","BBH","TBXU","LU1023059063.AUD","LU0868494617.USD","LU0889565916.HKD","BK4588","IBB","LU2468319806.SGD","LU0122379950.USD","LU0058720904.USD","IE00BFTCPJ56.SGD","LU1983299246.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4139","IE00B2B36J28.USD","IE0009355771.USD","SG9999001440.SGD","BK4585","BK4566","BK4581","LU2242652126.USD","LU2242646821.SGD","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665235617","title":"Amgen is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2665235617","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665235617?lang=en_us&edition=fundamental","pubTime":"2026-09-05 02:47","pubTimestamp":1788547620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMGN/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0130517989.USD","LU0889565916.HKD","IE0009355771.USD","LU1571399168.USD","BK4533","IE00BFTCPJ56.SGD","IBBQ","LU0942090050.USD","TFNS","LU0742534661.SGD","LU0417517546.SGD","IBB","BK4582","IYF","LU1074936037.SGD","LU0154236417.USD","FTXO","LU0130102774.USD","BBH","BK4534","BIB","LU1894683348.USD","LU1035773651.USD","PBE","BK4559","AMGN","LU0162691827.USD","LU1069347547.HKD","LU0175139822.USD","KBWB","LU0128525929.USD","LU1061106388.HKD","IE00B4R5TH58.HKD","LU1814569148.SGD","LU0106831901.USD","LU0310799852.SGD","LU0787776722.HKD","BK4588","LU0708994859.HKD","LU2361044949.HKD","LU0971096721.USD","LU2361044865.SGD","PGF","LU0868494617.USD","TBXU","LU0640476718.USD","IE0002270589.USD","IE00BJT1NW94.SGD","BK4581","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665935360","title":"This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935360","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665935360?lang=en_us&edition=fundamental","pubTime":"2026-09-05 00:13","pubTimestamp":1788538380,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals has won regulatory approval for a first-of-its kind drug targeting a rare brain disease, but Wall Street is shrugging off the news for a simple reason.Zilganersen, branded as Zan","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0889565916.HKD","LABU","IONS","BK4532","BK4588","BK4581","ARWR","XBI","LU0109394709.USD","PBE","BK4533","BIIB","LU0320765992.SGD","IE00B894F039.SGD","BK4139","LU0234570918.USD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664358347","title":"Alnylam's Zilebesiran Sees Commercial Opportunity From Baxfendy Launch, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664358347","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664358347?lang=en_us&edition=fundamental","pubTime":"2026-09-04 23:15","pubTimestamp":1788534956,"startTime":"0","endTime":"0","summary":"Alnylam Pharmaceuticals' (ALNY) zilebesiran product candidate could see a \"significant commercial opportunity\" from the solid launch of rival hypertension treatment Baxfendy, Oppenheimer said in a Thu","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","BK4548","LU2462157665.USD","LU0882574055.USD","LU2089984988.USD","LU1267930573.SGD","LU0058720904.USD","LU2237443978.SGD","LU0320765992.SGD","LU2456880835.USD","GNMX","PBE","LU0109394709.USD","BK4007","LU0128525929.USD","LU2417539215.USD","LU0289739699.SGD","LU0432979614.USD","LU1829250122.USD","LU2237443549.SGD","BK4139","LU2236285917.USD","BK4588","LU0708994859.HKD","AZN","LU0310800379.SGD","LU0114720955.EUR","LU2468319806.SGD","BK4585","LU2237443382.USD","LU2237443895.HKD","IE00B3T34201.USD","AZNH","LU2237443622.USD","ALNY","LU2237443465.HKD","BK4568","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664138186","title":"Correction: Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi","url":"https://stock-news.laohu8.com/highlight/detail?id=2664138186","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664138186?lang=en_us&edition=fundamental","pubTime":"2026-09-04 13:52","pubTimestamp":1788501121,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration  approved Eisai  and Biogen's subcutaneous autoinjector version of anti-amyloid beta protofibril antibody Leqembi as an initiation treatment for mild cognitive impairment due to Alzheimer's disease or mild AD dementia.The self-administered autoinjector is given once weekly at 500 mg through two 250 mg injections, according to a joint release on Thursday.The approval adds at-home subcutaneous treatment to the existing every-two-week intravenous regimen, with patients able to switch between the two administration methods during treatment, the release said.The product will be launched during Eisai's fiscal 2026, ending March 31, 2027.Shares of Eisai rose nearly 2% at market close.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","IE00B19Z9Z06.USD","IE00B894F039.SGD","BMED","BK4533","LU0109394709.USD","IE00B19Z9P08.USD","LU0320765992.SGD","BK4532","LU0234570918.USD","PBE","BK4139","LU0889565916.HKD","BIIB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664807150","title":"Stoke Therapeutics, Biogen present long-term data on Zorevunersen","url":"https://stock-news.laohu8.com/highlight/detail?id=2664807150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664807150?lang=en_us&edition=fundamental","pubTime":"2026-09-04 07:40","pubTimestamp":1788478812,"startTime":"0","endTime":"0","summary":"“Stoke Therapeutics (STOK) and Biogen Inc. (BIIB) announced presentations of data at the 16th European Epilepsy Congress taking place September 5-9...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/stoke-therapeutics-biogen-present-long-term-data-on-zorevunersen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/stoke-therapeutics-biogen-present-long-term-data-on-zorevunersen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IE00B894F039.SGD","LU0234570918.USD","BK4585","IE00B19Z9Z06.USD","BK4533","LU0320765992.SGD","BIIB","LU0109394709.USD","BK4539","PBE","EPV","BK4139","IE00B19Z9P08.USD","BK4532","LENZ","STOK","BMED","BK4007","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664807353","title":"Stoke Therapeutics, Biogen Report 4-Year Open-Label Data for Dravet Drug Zorevunersen Showing Durable Seizure Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2664807353","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664807353?lang=en_us&edition=fundamental","pubTime":"2026-09-04 07:30","pubTimestamp":1788478227,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics, Biogen report 4-year open-label data for Dravet drug zorevunersen showing durable seizure reductionStoke Therapeutics, Biogen flagged long-term zorevunersen data for Dravet syndrom","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDLCgQYh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4533","BK4532","LU0889565916.HKD","LU0320765992.SGD","STOK","BK4585","LU0109394709.USD","BK4139","PBE","BK4588","LU0234570918.USD","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BMED","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664380733","title":"Stoke Therapeutics and Biogen Present Long-Term Clinical Data That Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664380733","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664380733?lang=en_us&edition=fundamental","pubTime":"2026-09-04 07:30","pubTimestamp":1788478200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA8DKTRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4533","BMED","BIIB","BK4532","IE00B19Z9Z06.USD","LU0109394709.USD","LU0320765992.SGD","BK4139","PBE","IE00B894F039.SGD","BK4585","BK4588","IE00B19Z9P08.USD","STOK","LU0889565916.HKD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664803700","title":"Vortex Energy to Launch Ground Gravity Survey at Robinsons River Salt Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2664803700","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664803700?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:04","pubTimestamp":1788451496,"startTime":"0","endTime":"0","summary":"Vortex Energy Corp. ( ($TSE:VRTX) ) has issued an update. Vortex Energy Corp. plans to launch a targeted ground gravity survey at its wholly owned ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vortex-energy-to-launch-ground-gravity-survey-at-robinsons-river-salt-project?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vortex-energy-to-launch-ground-gravity-survey-at-robinsons-river-salt-project?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0061475181.USD","IE0002270589.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","LU1430594728.SGD","LU0109394709.USD","LU0289739699.SGD","LU2237438978.USD","LU1093756168.USD","VRTX","IE0002141913.USD","IE0009355771.USD","BIB","IE00BZ9MQY76.HKD","LU1069344957.HKD","LU2236285917.USD","IE00B19Z9P08.USD","SG9999013999.USD","IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","LU0079474960.USD","LU0234570918.USD","IE00BJT1NW94.SGD","BBH","LU0320765992.SGD","TBXU","GNMX","SGXZ57979304.SGD","BK4532","BK4585","IBB","BK4139","IBBQ","IDNA","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0417517546.SGD","LU0823416689.USD","LU1035775433.USD","LU1674673691.USD","LU2362541273.HKD","SG9999001176.SGD","LU0058720904.USD","IE00B4R5TH58.HKD","PBE","LU2324357040.USD","LU2362540622.SGD","LU2362541513.USD","IE00B19Z3581.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664741898","title":"Political and General News Events from September 3","url":"https://stock-news.laohu8.com/highlight/detail?id=2664741898","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664741898?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:26","pubTimestamp":1788438361,"startTime":"0","endTime":"0","summary":"DIARY-Political and General News Events from September 3Sept 3 (Reuters)-For other diaries, please see:Political and General NewsPOL/DIARYTop Economic EventsM/DIARYEmerging Markets Economic EventsEMRG","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL4N44V0YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","LU0058720904.USD","LU1023059063.AUD","LU2089984988.USD","BK4599","BBH","LU2112291526.USD","LU2242646821.SGD","LU1061106388.HKD","IE0002141913.USD","BK4566","LU2468319806.SGD","LU0889565916.HKD","BK4585","IE00B2B36J28.USD","BK4533","IE00BJJMRZ35.SGD","TBXU","SG9999001440.SGD","LU1983299246.USD","BK4581","IBBQ","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4139","IBB","LU0289739699.SGD","LU0122379950.USD","BK4534","LU2242652126.USD","LU0109394709.USD","PJP","IE00BJT1NW94.SGD","BK4588","IE0009355771.USD","BIB","LU1057294990.SGD","LU1571399168.USD","LU0868494617.USD","PBE","AMGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875497","title":"Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875497","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875497?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:10","pubTimestamp":1788430218,"startTime":"0","endTime":"0","summary":"Eisai (ESAIY) and Biogen (BIIB) announced that the National Medical Products Administration of China has approved the subcutaneous formulation, the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biogen-eisai-announce-nmpa-of-china-approves-subcutaneous-leqembi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biogen-eisai-announce-nmpa-of-china-approves-subcutaneous-leqembi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B894F039.SGD","IE00B19Z9P08.USD","BK4585","BK4007","ESAIY","LU0889565916.HKD","PBE","BK4532","BIIB","LU0109394709.USD","BK4533","LU0320765992.SGD","BK4139","IE00B19Z9Z06.USD","LU0234570918.USD","BMED","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664482770","title":"Sino Biopharmaceutical Stock Rises 6.3% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664482770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664482770?lang=en_us&edition=fundamental","pubTime":"2026-09-03 16:31","pubTimestamp":1788424260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rallied 6.3% to 5.59 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.4% to 25213.31.Sino Biopharmaceutical Ltd. closed 39% below its 52-week high of HK$9.12, which the company reached Sept. 10.The stock outperformed some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 4.8% and Amgen Inc. remained unchanged.Trading volume totaled 127.7 million shares, compared to the 50-day average of 101.5 million shares.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242646821.SGD","IBB","PJP","BK1191","BK4599","LU0868494617.USD","LU2089984988.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4566","BK4588","BK1521","IE00BZ08YT58.USD","LU0889565916.HKD","LU2112291526.USD","LU0320765992.SGD","BK4581","IE00BJT1NW94.SGD","LU0122379950.USD","BK4585","LU1061106388.HKD","LU2242652126.USD","LU1023059063.AUD","BK1589","IBBQ","BK4139","IE00B2B36J28.USD","LU1983299246.USD","01177","BIB","LU0289739699.SGD","BK1515","SG9999001440.SGD","AMGN","BK4534","LU1057294990.SGD","LU1571399168.USD","TBXU","BK4533","IE0009355771.USD","LU2468319806.SGD","IE0002141913.USD","LU0058720904.USD","LU0109394709.USD","PBE","IE00BJJMRZ35.SGD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BBH","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664823499","title":"Biogen : Piper Sandler Raises Target Price to $245 from $225","url":"https://stock-news.laohu8.com/highlight/detail?id=2664823499","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664823499?lang=en_us&edition=fundamental","pubTime":"2026-09-03 11:00","pubTimestamp":1788404422,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nFWN44U0YT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU0234570918.USD","PBE","BIIB","BK4533","BK4585","BK4532","LU0320765992.SGD","BK4139","BMED","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","LU0109394709.USD","BK4588","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}